Advertisement

Interaction of Taspine Derivative TPD7 with Vascular Endothelial Growth Factor Receptor 2 by Cell Membrane Chromatography

  • Liu Yang
  • Yingnan Zeng
  • Nan Ma
  • Weina MaEmail author
Original
  • 7 Downloads

Abstract

Affinity chromatography, as one of the important tools for studying the binding affinity between ligands and receptors, plays a key role in the process of screening and analyzing active compounds. Cell membrane chromatography (CMC) utilizes cell membrane receptors as stationary phases to perform screening and binding affinity of compounds with specific receptors whose three-dimensional configurations and biological activities were largely retained. In this study, a highly vascular endothelial growth factor receptor 2 (VEGFR2) expressing CMC method was established to investigate the binding affinity between TPD7 and VEGFR2. Competitive binding study taking sunitinib malate as the marker was used to inspect the binding site of TPD7 on VEGFR2. Results showed that TPD7 shared the same binding site with sunitinib on VEGFR2, which was consistent with the results of molecular docking. The equilibrium dissociation constants (KD) of TPD7 was (0.29 ± 0.02) × 10−6 M. Furthermore, TPD7 could alter the VEGFR2 kinase and significantly decrease phosphorylation of VEGFR2 in a dose-dependent manner. The studies showed that TPD7 could bind to VEGFR2 and then down-regulate the phosphorylation of VEGFR2.

Graphic Abstract

Keywords

Cell membrane chromatography Competitive binding Equilibrium dissociation constant VEGFR2 TPD7 

Notes

Acknowledgements

This study was supported by National Natural Science Foundation of China (Grant no. 81603148), the National Science Foundation for Post-doctoral Scientists of China (Grant no. 2016M592806), and the Fundamental Research Funds for the Central Universities (Grant no. xzy012019078).

Compliance with ethical standards

Conflict of interest

The authors declare that there are no conflicts of interest.

References

  1. 1.
    Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669CrossRefGoogle Scholar
  2. 2.
    Terman BI, Carrion ME, Kovacs E, Rasmussen BA, Eddy RL, Shows TB (1991) Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6:1677–1683Google Scholar
  3. 3.
    Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M (1990) Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5:519–524Google Scholar
  4. 4.
    Huang X, Zhou G, Wu W, Ma G, D’Amore PA, Mukai S, Lei H (2017) Editing VEGFR2 blocks VEGF-induced activation of Akt and tube formation. Investig Ophthalmol Vis Sci 58:1228–1236CrossRefGoogle Scholar
  5. 5.
    Liu Z, Qi L, Li Y, Zhao X, Sun B (2017) VEGFR2 regulates endothelial differentiation of colon cancer cells. BMC Cancer 17:593CrossRefGoogle Scholar
  6. 6.
    Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795–803CrossRefGoogle Scholar
  7. 7.
    Hajari Taheri F, Hassani M, Sharifzadeh Z, Behdani M, Arashkia A, Abolhassani M (2019) T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy. IUBMB Life.  https://doi.org/10.1002/iub Google Scholar
  8. 8.
    Lanitis E, Irving M, Coukos G (2015) Targeting the tumor vasculature to enhance T cell activity. Curr Opin Immunol 33:55–63CrossRefGoogle Scholar
  9. 9.
    Padró T, Bieker R, Ruiz S, Steins M, Retzlaff S, Bürger H, Büchner T, Kessler T, Herrera F, Kienast J (2002) Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 16:1302–1310CrossRefGoogle Scholar
  10. 10.
    Kanagawa N, Yanagawa T, Nakagawa T, Okada N, Nakagawa S (2013) Tumor vessel-injuring ability improves antitumor effect of cytotoxic T lymphocytes in adoptive immunotherapy. Cancer Gene Ther 20:57–64CrossRefGoogle Scholar
  11. 11.
    Kolch W (2000) Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351(Pt 2):289–305CrossRefGoogle Scholar
  12. 12.
    Koch S, Claesson-Welsh L (2012) Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med 2:a006502CrossRefGoogle Scholar
  13. 13.
    Farzaneh Behelgardi M, Zahri S, Mashayekhi F, Mansouri K, Asghari SM (2018) A peptide mimicking the binding sites of VEGF-A and VEGF-B inhibits VEGFR-1/-2 driven angiogenesis, tumor growth and metastasis. Sci Rep 8:17924CrossRefGoogle Scholar
  14. 14.
    Zheng X, Zhang Y, Zhang L, Xu W, Ma W, Sun R, Zeng H (2016) Synergistic inhibition of sunitinib and ethaselen against human colorectal cancer cells proliferation. Biomed Pharmacother 83:212–220CrossRefGoogle Scholar
  15. 15.
    Li YP, He L (2007) Establishment of the model of vascular endothelial cell membrane chromatography and its preliminary application. Chin Sci Bull 52:922–928CrossRefGoogle Scholar
  16. 16.
    Zhang Y, He L, Meng L, Luo W (2008) Taspine isolated from Radix et Rhizoma Leonticis inhibits proliferation and migration of endothelial cells as well as chicken chorioallantoic membrane neovascularisation. Vasc Pharmacol 48:129–137CrossRefGoogle Scholar
  17. 17.
    Zhao J, Zhao L, Chen W, He L, Li X (2008) Taspine downregulates VEGF expression and inhibits proliferation of vascular endothelial cells through PI3 kinase and MAP kinase signaling pathways. Biomed Pharmacother 62:383–389CrossRefGoogle Scholar
  18. 18.
    Zhang J, Zhang YM, Pan XY, Wang SC, He LC (2011) Synthesis and cytotoxic evaluation of novel symmetrical taspine derivatives as anticancer agents. Med Chem 7:286–294CrossRefGoogle Scholar
  19. 19.
    Zhan Y, Li J, Ma W, Zhang D, Luo W (2016) Characterization of interactions between taspine derivate TPD7 and EGF receptor by cell membrane chromatography with zonal elution and frontal analysis, chromatographia. Chromatographia 79:1585–1592CrossRefGoogle Scholar
  20. 20.
    Zhan Y, Zhang H, Li J, Zhang Y, Zhang J, He LC (2015) A novel biphenyl urea derivate inhibits the invasion of breast cancer through the modulation of CXCR20. J Cell Mol Med 19:1614–1623CrossRefGoogle Scholar
  21. 21.
    Zhan Y, Zhang Y, Liu C, Zhang J, Smith WW, Wang N, Chen Y, Zheng L, He L (2012) A novel taspine derivative, HMQ1611, inhibits breast cancer cell growth via estrogen receptor alpha and EGF receptor signaling pathways. Cancer Prev Res 5:864–873CrossRefGoogle Scholar
  22. 22.
    Zhang J, Zhang Y, Shan Y, Li N, Ma W, He LC (2010) Synthesis and preliminary biological evaluation of novel taspine derivatives as anticancer agents. Eur J Med Chem 45:2798–2805CrossRefGoogle Scholar
  23. 23.
    Hou XF, Wang SC, Zhang T, Ma J, Zhang J, Zhang YM, Lu W, He HZ, He LC (2014) Recent advances in cell membrane chromatography for traditional Chinese medicines analysis. J Pharm Biomed 101:141–150CrossRefGoogle Scholar
  24. 24.
    Ma WY, Xie YY, Wang YM, Luo GA (2017) Emerging application and reflections of cell membrane chromatography in the quality evaluation of traditional Chinese medicine. Acta Pharmaceutica Sinica 52:1827–1838Google Scholar
  25. 25.
    Imai K, Tamura K, Tanigaki T, Takizawa M, Nakayama E, Taniguchi T, Okamoto M, Nishiyama Y, Tarumoto N, Mitsutake K, Murakami T, Maesaki S, Maeda T (2018) Whole genome sequencing of influenza A and B viruses with the MinION sequencer in the clinical setting: a pilot study. Front Microbiol 9:2748CrossRefGoogle Scholar
  26. 26.
    Chen XF, Cao Y, Zhang H, Zhu ZY, Liu M, Liu HB, Ding X, Hong ZY, Li WH, Lv DY, Wang LR, Zhuo XY, Zhang JP, Xie XQ, Chai YF (2014) Comparative normal/failing rat myocardium cell membrane chromatographic analysis system for screening specific components that counteract doxorubicin-induced heart failure from Acontium carmichaeli. Anal Chem 86:4748–4757CrossRefGoogle Scholar
  27. 27.
    Du H, Wang S, Ren J, Lv N, He L (2012) Revealing multi-binding sites for taspine to VEGFR-2 by cell membrane chromatography zonal elution. J Chromatogr B 887–888:67–72CrossRefGoogle Scholar
  28. 28.
    Huang J, Tang Q, Wang C, Yu H, Feng Z, Zhu J (2015) Molecularly targeted therapy of human hepatocellular carcinoma xenografts with radio-iodinated anti-VEGFR2 Murine-human chimeric fab. Sci Rep 5:10660CrossRefGoogle Scholar
  29. 29.
    Hage DS, Noctor TA, Wainer IW (1995) Characterization of the protein binding of chiral drugs by high-performance affinity chromatography. Interactions of R- and S-ibuprofen with human serum albumin. J Chromatogr A 693:23–32CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.School of Pharmacy, Health Science CenterXi’an Jiaotong UniversityXi’anPeople’s Republic of China
  2. 2.State Key Laboratory of Shaanxi for Natural Medicines Research and EngineeringXi’anPeople’s Republic of China

Personalised recommendations